Drug Profile
Bevantolol - SOM Biotech
Alternative Names: Bevantolol-hydrochloride; CI-775; NC-1400; SOM-3355Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Nippon Chemiphar
- Developer SOM Biotech
- Class Antidementias; Antihypertensives; Ischaemic heart disorder therapies; Neuroprotectants; Phenethylamines; Phenyl ethers; Propanolamines; Small molecules
- Mechanism of Action Beta 1 adrenergic receptor antagonists; Vesicular monoamine transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Huntington's disease
Most Recent Events
- 28 Mar 2022 SOM Biotech initiates a phase II trial in Huntington's disease (In adults, In the elderly) in Spain (PO) (EudraCT2021-003453-28) (NCT05475483)
- 15 Dec 2021 SOM Biotech plans a phase IIb trial for Huntington’s disease in the first quarter of 2022
- 15 Dec 2021 MegaPharm enters into distribution and marketing agreement with SOM Biotech for Bevantolol in Israel